Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 3/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP12 | P39900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5907185 | 0.67 | AR (0.33) | ARDAO | |
| SCHEMBL5205493 | 0.64 | TAAR1 (0.46) | ARDAOTP53 | |
| SCHEMBL113326 | 0.56 | TAAR1 (0.48) | MMP1MMP2MMP9MMP12 | |
| SCHEMBL3163556 | 0.56 | TAAR1 (0.43) | DAO | |
| SCHEMBL1047600 | 0.56 | TAAR1 (0.43) | ARDAOCA12MMP1MMP2 | |
| SCHEMBL7701701 | 0.55 | TAAR1 (0.52) | DAO | |
| SCHEMBL20117761 | 0.54 | DAO (0.38) | ARDAOMMP1MMP2MMP9 | |
| SCHEMBL13615074 | 0.53 | TAAR1 (0.44) | DAOMMP1MMP2MMP9MMP12 | |
| SCHEMBL6206211 | 0.53 | TAAR1 (0.45) | ARDAOCA12MMP1MMP2 | |
| SCHEMBL2141552 | 0.53 | TAAR1 (0.40) | ARDAOCA12MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060106044-A1 | Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4-oxopyrimidines | IDENIX PHARMACEUTICALS INC. (US) | 2006-05-18 | — | — | US | disclosed |
| US-20040092539-A1 | Substituted 6-benzyl-4-oxopyrimidines, process for their preparation and pharmaceutical compositions containing them | COLLA PAOLO LA (IT) | 2004-05-13 | — | — | US | disclosed |
| US-20030225114-A1 | Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4- oxopyrimidines | IDENIX PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| US-6635636-B1 | Reverse transcriptase inhibitors; human immunodeficiency virus and acquired immune deficiency syndrome | IDENIX PHARMACEUTICALS, INC. | 2003-10-21 | — | — | US | disclosed |
| EP-1343502-A2 | METHODS FOR INHIBITING THE TRANSMISSION OF HIV USING TOPICALLY APPLIED SUBSTITUTED 6-BENZYL-4-OXOPYRIMIDINES | Idenix (Cayman) Limited (KY) | 2003-09-17 | — | — | EP | disclosed |
| US-6545007-B2 | Topically applying to the skin or epithelial tissue of a human an effective amount of a dihydro-alkyloxy-benzyl-oxopyrimidine compound for inhibiting sexual transmission of HIV | IDENIX (CAYMAN) LIMITED (KY) | 2003-04-08 | — | — | US | disclosed |
| US-20030008887-A1 | Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4-oxopyrimidines | IDENIX PHARMACEUTICALS INC. | 2003-01-09 | — | — | US | disclosed |
| WO-2002040021-A2 | METHODS FOR INHIBITING THE TRANSMISSION OF HIV USING TOPICALLY APPLIED SUBSTITUTED 6-BENZYL-4-OXOPYRIMIDINES | IDENIX (CAYMAN) LIMITED (KY) | 2002-05-23 | — | — | WO | disclosed |
| EP-1098887-A1 | SUBSTITUTED 6-BENZYL-4-OXOPYRIMIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Novirio Pharmaceuticals Limited (KY) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000003998-A1 | SUBSTITUTED 6-BENZYL-4-OXOPYRIMIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NOVIRIO PHARMACEUTICALS LIMITED (KY) | 2000-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106044-A1 | Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4-oxopyrimidines | DUT, UNG, NUDT1 | AR 1035/4885DAO 22/4885CA12 4868/4885 |
| US-20030008887-A1 | Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4-oxopyrimidines | DUT, UNG, NUDT1 | AR 1410/4885DAO 14/4885CA12 4858/4885 |
| US-20040092539-A1 | Substituted 6-benzyl-4-oxopyrimidines, process for their preparation and pharmaceutical compositions containing them | TYMP, UMPS, TYMS | AR 4144/4885DAO 422/4885CA12 4865/4885 |
| US-20030225114-A1 | Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4- oxopyrimidines | DUT, UNG, NUDT1 | AR 1410/4885DAO 14/4885CA12 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.